Crescent Biopharma (CBIO) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Evotec (EVO) over the past year, gaining 17.1% versus a loss of 60.6%. Over five years, CBIO leads with a -92.9% price change compared with -93.1% for EVO. Crescent Biopharma is the larger company by market cap ($548.3 million vs $545.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | EVO |
|---|---|---|
| Share price | $14.76 | $1.54 |
| Market cap | $548.29M | $545.52M |
| 1-day change | +4.53% | -2.23% |
| YTD return | +19.06% | -49.03% |
| 1-year return | +17.08% | -60.55% |
| 5-year return | -92.87% | -93.05% |
| EPS (TTM) | $-7.63 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $4.27 |
| 52-week low | $8.72 | $1.50 |
| Distance from 52-week high | -46.15% | -64.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +113.41% | +171.01% |
| Average volume | 399.18K | 105.22K |
| Shares outstanding | 37.14M | 355.39M |
| Employees | 69 | 4,461 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed EVO by 77.6 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
CBIO vs EVO FAQ
Which is bigger, Crescent Biopharma or Evotec?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $548.29M compared with $545.52M for Evotec (EVO).
Which stock has performed better over the past year, CBIO or EVO?
CBIO returned +17.08% over the past 12 months, compared with -60.55% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.